Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16446383 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Radomska HS, et al. (2006) Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 203, 371-81 16446383
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S21-p - C/EBP-alpha (human) ▲
Orthologous residues
C/EBP‑alpha (human): S21‑p, C/EBP‑alpha (mouse): S21‑p, C/EBP‑alpha (rat): S21‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), Molm 14 (myeloid), Mono Mac 1 (myeloid), Mono Mac 6 (myeloid), MV4-11 (myeloid), THP1 (myeloid)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human
 Comments:  Molm 13; leukemic blasts from bone marrow (patient 592) and peripheral blood (patient 667).
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase
decrease MLN-518
AG1296 decrease
PD98059 decrease
no change compared to control STI571
Downstream Regulation
 Effect of modification (function):  inhibition
 Effect of modification (process):  cell differentiation, altered
 Comments:  C/EBP-a S21A mutation promoted granulocytic differentiation; S21D inhibited it (via maintaining c-myc expression).

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), Molm 14 (myeloid), Mono Mac 1 (myeloid), Mono Mac 6 (myeloid), MV4-11 (myeloid), THP1 (myeloid)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human
 Comments:  Molm 13; leukemic blasts from bone marrow (patient 592) and peripheral blood (patient 667).
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase
decrease MLN-518
AG1296 decrease

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), Molm 14 (myeloid), Mono Mac 1 (myeloid), Mono Mac 6 (myeloid), MV4-11 (myeloid), THP1 (myeloid)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human
 Comments:  Molm 13; leukemic blasts from bone marrow (patient 592) and peripheral blood (patient 667).
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase
decrease MLN-518
AG1296 decrease

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), Molm 14 (myeloid), Mono Mac 1 (myeloid), Mono Mac 6 (myeloid), MV4-11 (myeloid), THP1 (myeloid)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human
 Comments:  Molm 13; leukemic blasts from bone marrow (patient 592) and peripheral blood (patient 667).
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase
decrease MLN-518
AG1296 decrease

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), Molm 14 (myeloid), Mono Mac 1 (myeloid), Mono Mac 6 (myeloid), MV4-11 (myeloid), THP1 (myeloid)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human
 Comments:  Molm 13; leukemic blasts from bone marrow (patient 592) and peripheral blood (patient 667).
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase
decrease MLN-518
AG1296 decrease

Y591-p - FLT3 (human) ▲
Orthologous residues
FLT3 (human): Y591‑p, FLT3 (mouse): Y592‑p, FLT3 iso3 (mouse): Y592‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), Molm 14 (myeloid), Mono Mac 1 (myeloid), Mono Mac 6 (myeloid), MV4-11 (myeloid), THP1 (myeloid)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human
 Comments:  Molm 13; leukemic blasts from bone marrow (patient 592) and peripheral blood (patient 667).
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
decrease MLN-518


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.